GENE ONLINE|News &
Opinion
Blog

Cancer
Trials & Approvals PARP Inhibitor
AZ, Merck’s PARP Inhibitor Shines in Phase 3 Prostate Cancer Trial
2021-09-26
Special Cancer
How Patients with dMMR/MSI-H Tumors Can Benefit from Immunotherapy?
2021-09-24
Special
ESMO21: Latest Clinical Studies Answer Central Questions in the Treatment of Leading Cancers
2021-09-22
Trials & Approvals Cancer
Seagen, Genmab’s Antibody Drug Conjugate Bags FDA Approval for Cervical Cancer
2021-09-22
Special
Day 2 ESMO 2021 Roundup: New Paradigms for Long-Term Cancer Care and Immunotherapies for High Risk Metastatic Cancers
2021-09-19
Special
EQRx, CStone’s Low-Cost anti-PD-L1 Inhibitor Flaunts Encouraging Data in Stage 3 NSCLC
2021-09-19
Special
Day 1 ESMO 2021 Roundup: Investigational Immunotherapies Show Promise in Early Cancer Trials
2021-09-18
Special
ESMO21: Experts Debate Whether MRD Diagnosis Can Improve Cure Rates in Solid Tumors
2021-09-17
MD Anderson to Develop Microbiome Cancer Therapeutics with CRISPR Gene-Editing
2021-09-14
Trials & Approvals Lung Cancer
NHS to Roll Out Revolutionary Lung Cancer Drug Targeting the Once ‘Undruggable’ KRAS
2021-09-12
China Investigational New Drug
Innovent to Send the First-Ever SIRPa Targeting Antibody to Human Trials in China
2021-09-10
Novel Mutational Patterns Explain Evolution of Lung Cancer in Never-Smokers
2021-09-09
Trials & Approvals FDA Approval
BeiGene’s Brukinsa Bags Second FDA Approval, to Rival Imbruvica in Treating a Rare Cancer
2021-09-06
Trials & Approvals
J&J’s FDA-Approved Bispecific Antibody Registers Promising Phase 1 Results for a Different Indication
2021-08-20
M&A Federal Trade Commission
Illumina Completes GRAIL Acquisition Without Approval From FTC
2021-08-19
1 … 5 6 7 8 9 … 22
LATEST
Revolutionizing Treatment: ASGCT’s Clinical Trials Spotlight on Immunotherapy, Cancer Vaccines, and Auditory Diseases
2024-05-09
Advancing Health: ASGCT’s Clinical Trials Spotlight on Cell Therapy and Cell-Based Gene Therapy
2024-05-09
Infinitopes’ Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
2024-05-09
Profluent Achieves Human Genome Editing Milestone Using OpenCRISPR-1: The First AI-Generated, Open-Source Gene Editor
2024-05-08
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top